Glioblastoma Multiforme (GBM) is recognized as one of the most aggressive and lethal forms of brain cancer, with an annual incidence of approximately 5 cases per 100,000 individuals and a median survival rate of less than 15 months. A significant clinical challenge associated with GBM is the occurrence of seizures, which manifest as the first symptoms in 40%-45% of patients. The underlying mechanisms that contribute to the epileptogenic nature of GBM remain poorly understood, primarily due to the difficulties in developing clinically relevant animal models and the complexities surrounding the latent period of seizure onset. In a pivotal study, researchers utilized a CRISPR-induced pluripotent stem cell (IUE) GBM rat model to investigate these mechanisms. Continuous video-EEG monitoring allowed for the detection of early interictal and ictal events, providing insights into the timing and nature of seizure activity in relation to tumor development (ref: Hu doi.org/10.1016/j.neulet.2021.136351/). This model closely mirrors the pathological and clinical features observed in human patients, thereby enhancing the understanding of GBM-related seizures and paving the way for potential therapeutic interventions. The findings underscore the importance of early detection and intervention in managing seizures associated with GBM, highlighting the need for further research into the specific pathways involved in tumor-induced epileptogenesis.